Anti-resorptives in the management of osteoporosis

Best Practice and Research: Clinical Endocrinology and Metabolism

Volumn 22, Issue 5, 2008, Pages 849-868

  Miller, Paul D ^a  

^a University of Colorado Health Sciences Center   (United States)

Author keywords

anti resorptive; bisphosphonates; bone mineral density; bone turnover; calcitonin; denosumab; estrogens; fragility fractures; non vertebral fractures; osteoporosis; selective estrogen receptor modulators; tibolone; vertebral fractures

Indexed keywords

AGENTS AFFECTING METABOLISM; ALENDRONIC ACID; ANTIRESORPTIVE AGENT; BAZEDOXIFENE; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CONJUGATED ESTROGEN; DENOSUMAB; ESTROGEN; ETIDRONIC ACID; IBANDRONIC ACID; MEDROXYPROGESTERONE ACETATE; PLACEBO; RALOXIFENE; RISEDRONIC ACID; SALCATONIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TIBOLONE; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

BONE DENSITY; BONE MINERAL; BONE MINERALIZATION; BONE NECROSIS; BONE STRENGTH; BONE TURNOVER; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TRANSFORMATION; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; EVIDENCE BASED MEDICINE; FRAGILITY FRACTURE; GASTROINTESTINAL SYMPTOM; HEART ATRIUM FIBRILLATION; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; JAW DISEASE; KIDNEY FAILURE; LOW DRUG DOSE; MONOTHERAPY; NAUSEA; NEPHROTOXICITY; NONHUMAN; NOSE IRRITATION; OSTEOLYSIS; OSTEOMALACIA; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; RECOMMENDED DRUG DOSE; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SIDE EFFECT; SKIN ALLERGY; TREATMENT DURATION; VERTEBRA FRACTURE;

BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; FEMALE; FRACTURES, BONE; HUMANS; MALE; OSTEOPOROSIS;

EID: 56349160610     PISSN: 1521690X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beem.2008.07.004     Document Type: Review

References (114)

1. Burr D.B., and Turner C.H. Biomechanics of bone. In: Favus M. (Ed). Primer on the metabolic bone diseases and disorders of mineral metabolism (2003), American Society for Bone and Mineral Research, Washington, DC 58-64
2. Heaney R. Remodeling and skeletal fragility. Osteoporosis International 14 S 5 (2003) S12-S15
3. Pivonka P., Zimak J., Smith D.W., et al. Model structure and control of bone remodeling: a theoretical study. Bone 43 2 (2008) 249-263
4. Huang J.C., Sakata T., Pfleger L.L., et al. PTH differentially regulates expression of RANKL and OPG. Journal of Bone and Mineral Research 19 4 (2004) 235-244
5. Boyle W.J., Simonet W.S., and Lacey D.L. Osteoclast differentiation and activation. Nature 423 6937 (2003) 337-342
6. Bekker P.J., Holloway D.L., Rasmussen A.S., et al. Single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. Journal of Bone and Mineral Research 19 7 (2004) 1059-1066
7. Bonewald L.F., and Johnson M.L. Osteocytes, mechanosensing, and Wnt signaling. Bone 42 4 (2008) 606-615
8. Bonewald L.F. Osteocytes: a proposed multifunctional bone cell. Journal of Musculoskeletal & Neuronal Interactions 2 3 (2002) 239-241
9. Piters E., Boudin E., and Van Hul W. Wnt signaling: a win for bone. Archives of Biochemistry and Biophysics 473 2 (2008) 112-116
10. Ten Dijke P., Krause C., de Gorter D.J., et al. Osteocyte-derived sclerostin inhibits bone formation: its role in bone morphogenetic protein and Wnt signaling. The Journal of Bone and Joint Surgery 90 1 (2008) 31-35
11. Duque G. Bone and fat connection in aging bone. Current Opinion in Rheumatology 20 4 (2008) 429-434
12. Rosen C.J., and Bouxsein M.L. Mechanisms of disease: is osteoporosis the obesity of bone?. Nature Clinical Practice Rheumatology 2 1 (2006) 35-43
13. Davison K.S., Siminoski K., Adachi J.D., et al. The effects of antifracture therapies on the components of bone strength: assessment of fracture risk today and in the future. Seminars in Arthritis and Rheumatism 36 1 (2006) 10-21
14. Miller P.D. The treatment of osteoporosis: anti-resorptive therapy. In: Rosen) C. (Ed). Clinics in laboratory medicine (2000), W.B. Saunders Co., Philadelphia, PA 603-622
15. Rossouw J.E., Anderson G.L., Prentice R.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. The Journal of the American Medical Association 288 3 (2002) 321-333
16. Jackson R.D., and Shidham S. The role of hormone therapy and calcium plus vitamin D for reduction of bone loss and risk for fractures: lessons learned from the Women's Health Initiative. Current Osteoporosis Reports 5 4 (2007) 153-159
17. Cauley J.A., Robbins J., Chen Z., et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. The Journal of the American Medical Association 290 13 (2003 Oct 1) 1729-1738
18. Lindsay R. Hormones and bone health in postmenopausal women. Endocrine 24 3 (2004) 223-230
19. Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American menopause society. Menopause 15 4 (2008) 584-602
20. Kirahnan V., Heath H., and Bryant H.U. Mechanism of action of estrogens and selective estrogen receptor modulators. Vitamins and Hormones 60 (2000) 123-147
21. Ettinger B., Black D.M., Mitlak B.H., et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) investigators. The Journal of the American Medical Association 282 7 (1999) 637-645
22. Miller P.D., Chines A.A., Christiansen C., et al. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study. Journal of Bone and Mineral Research 4 (2008) 525-535
23. Bevers R. The STAR trial: evidence for raloxifene as a breast cancer risk reduction agent for postmenopausal women. Journal of the National Comprehensive Cancer Network 5 8 (2007) 719-724
24. Jordan V.C. The rise of raloxifene and the fall of invasive breast cancer. Journal of the National Cancer Institute 100 12 (2008 Jun 18) 831-833
25. Notelovitz M. Postmenopausal tibolone therapy: biologic principles and applied clinical practice. Medscape General Medicine 9 1 (2007 Jan 3) 2
26. Prelevic G.M., Markou A., Arnold A., et al. The effect of tibolone on bone mineral density in postmenopausal women with osteopenia or osteoporosis - 8 years follow-up. Maturitas 47 3 (2004) 229-234
27. Ettinger B. Tibolone for the prevention and treatment of postmenopausal osteoporosis. Maturitus 57 1 (2007 May 20) 35-38
28. Delmas P.D., Davis S.R., Hensen J., et al. Effects of tibolone and raloxifene on bone mineral density in osteopenic postmenopausal women. Osteoporosis International (2008)
29. Karsdal M.A., Henriksen K., Arnold M., et al. Calcitonin - a drug of the past or for the future? Physiologic inhibition of bone resorption while sustaining osteoclast numbers improves bone quality. Biodrugs 22 3 (2008) 137-144
30. Body J.J. Calcitonin for the long-term prevention and treatment of postmenopausal osteoporosis. Bone 30 5 (2002) 75S-79S
31. Siminoski K., and Josse R.G. Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 9. Calcitonin in the treatment of osteoporosis. Canadian Medical Association Journal 155 7 (1996) 962-965
32. Chesnut III C.H., Silverman S., Andriano K., et al. Randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. The American Journal of Medicine 109 4 (2000) 267-276
33. Chesnut III C.H., Majumdar S., Newitt D.C., et al. Effects of salmon calcitonin on trabecular microarchitecture as determined by magnetic resonance imaging: results from the QUEST study. Journal of Bone and Mineral Research 20 9 (2005) 1548-1561
34. Chesnut III C.H., Azria M., Silverman S., et al. Salmon calcitonin: a review of current and future therapeutic indications. Osteoporosis International 19 4 (2008) 479-491
35. Fleisch H., Russell R.G., and Francis D. Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science 165 (1969) 1262-1264
36. Russell R.G., Muhlbauer Rc S., Bisaz D., et al. The influence of pyrophosphate, condensed phosphates, phosphonates and other phosphate compounds on the dissolution of hydroxyapetite in vitro and on bone resorption induced by parathyroid hormone in tissue culture and in thyroparathyroidectomized rats. Calcified Tissue Research 6 (1970) 183-189
37. Russell R.G.G., and Rogers M. Bisphosphonates: from the laboratory to the clinic and back again. Bone 25 (1999) 97-106
38. Rogers M. New insights into the molecular mechanisms of action of bisphosphonates. Current Pharmaceutical Design 9 (2003) 2643-2658
39. Nancollas G.H., Tang R., Phipps R.J., et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapetite. Bone 38 (2006) 617-627
40. Plotkin L.I., Manolagas S.C., and Bellido T. Dissociation of the pro-apoptotic effects of bisphosphonates on osteoclasts from their anti-apoptotic effects on osteoblasts/osteocytes with novel analogs. Bone 39 (2006) 443-452
41. Russell R.G.G., Watts N.B., Ebetino F.H., et al. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporosis International 19 (2008) 733-759
42. Miller P.D. Bisphosphonates: pharmacology and use in the treatment of osteoporosis. In: Marcus R., Feldman D., Nelson D.A., and Rosen C.J. (Eds). Osteoporosis. 3rd ed. (2007), Elsevier Academic Press, San Diego, CA 1725-1736
43. Papapoulos S. Who will benefit from anti-resorptive treatment (bisphosphonates)?. Best Practice & Research. Clinical Rheumatology 19 6 (2005) 965-973
44. Miller P.D. Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy. Clinical Therapeutics 27 4 (2005) 1-16
45. Miller P.D. Bone density and markers of bone turnover in predicting fracture risk and how changes in these measures predict fracture risk reduction. Current Osteoporosis Reports 3 3 (2005) 103-110
46. Black D.M., Delmas P.D., Eastell R., et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. The New England Journal of Medicine 356 18 (2007) 1809-1822
47. Watts N.B., Harris S.T., Genant H.K., et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. The New England Journal of Medicine 323 2 (1990) 73-79
48. Kleerekoper M., Peterson E.L., Nelson D., et al. A randomized trial of sodium fluoride as a treatment for postmenopausal osteoporosis. Osteoporosis International 1 3 (1991) 155-161
49. van Staa T.P., Abenhaim L., and Cooper C. Use of cyclical etidronate and prevention of non-vertebral fractures. British Journal of Rheumatology 37 1 (1998) 87-94
50. Storm T., Steiniche T., Thamsborg G., et al. Changes in bone histomorphometry after long-term treatment with intermittent, cyclic etidronate for postmenopausal osteoporosis. Journal of Bone and Mineral Research 8 2 (1993) 199-208
51. Black D.M., Cummings S.R., Karpf D.B., et al. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348 (1998) 1535-1541
52. Cummings S.R., Black D.M., Thompson D.E., et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. The Journal of the American Medical Association 280 (1998) 2077-2082
53. Pols H.A., Felsenberg D., Hanley D.A., et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporosis International 9 5 (1999) 461-468
54. Bonnick S.L., Saag K.G., Kiel D.P., et al. Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years. The Journal of Clinical Endocrinology and Metabolism 91 7 (2006) 2631-2637
55. Miller P.D., Hochberg M.C., Wehren L.E., et al. How useful are measures of BMD and bone turnover?. Current Medical Research and Opinion 21 4 (2005) 545-554
56. Miller P.D. Monitoring osteoporosis therapies. Current Osteoporosis Reports 5 (2007) 38-43
57. Wasnich R.D., and Miller P.D. Antifracture efficacy of antiresportive agents are related to changes in bone density. Clinics in Endocrinology and Metabolism 85 (2000) 1-6
58. Cummings S.R., Karpf D.B., Harris F., et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with anti-resorptive drugs. The American Journal of Medicine 112 (2002) 281-289
59. Bonnick S.L., and Shulman L. Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both?. The American Journal of Medicine 119 4 Suppl. 1 (2006) S25-S31
60. Watts N.B., Geusens P., Barton I.P., et al. Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD. Journal of Bone and Mineral Research 20 12 (2005) 2097-2104
61. Seeman E. Is a change in bone mineral density a sensitive and specific surrogate of anti-fracture efficacy?. Bone 41 3 (2007) 308-317
62. Borah B., Dufresne T.E., Chmielewski P.A., et al. Risedronate preserves trabecular architecture and increases bone strength in vertebra of ovariectomized minipigs as measured by three-dimensional microcomputed tomography. Journal of Bone and Mineral Research 17 7 (2002) 1139-1147
63. Borah B., Dufresne T.E., Ritman T.L., et al. Long-term risedronate treatment normalizes mineralization and continues to preserve trabecular architecture: sequential triple biopsy studies with micro-computed tomography. Bone 39 2 (2006) 345-352
64. Bauss F., and Dempster D.W. Effects of ibandronate on bone quality: preclinical studies. Bone 40 2 (2007) 265-273
65. Seeman E., and Delmas P.D. Bone quality - the material and structural basis of bone strength and fragility. The New England Journal of Medicine 354 21 (2006 May 25) 2250-2261
66. Seeman E. Bone quality: the material and structural basis of bone strength. Journal of Bone and Mineral Metabolism 26 1 (2008) 1-8
67. Lewiecki EM, Watts NB. Assessing response to osteoporosis therapy. Osteoporosis International (in press).
68. Black D.M., Schwartz A.V., Ensrud K.E., et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term extension (FLEX): a randomized trial. The Journal of the American Medical Association 296 24 (2006) 2927-2938
69. Curtis JR, Westfall AO, Cheng H, et al. Risk of hip fracture after bisphosphonate discontinuation: implications for a drug holiday. Osteoporosis International (in press).
70. Watts N.B., Chines A., Olszynski W.P., et al. Fracture risk remains reduced one year after discontinuation of risedronate. Osteoporosis International 19 3 (2008) 365-372
71. Harris S.T., Watts N.B., Genant H.K., et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. The Journal of the American Medical Association 282 (1999) 1344-1352
72. Reginster J.-Y., Minne H., Sorenson O.H., et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporosis International 11 (2000) 83-91
73. Sorenson O.H., Crawford G.M., Mulder H., et al. Long term efficacy of risedronate: a 5 year clinical experience. Bone 32 (2003) 120-126
74. Liberman U.A., Weiss S.R., Broll J., et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The New England Journal of Medicine 333 (1995) 1437-1443
75. Chesnut III C.H., Skag A., Christiansen C., et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. Journal of Bone and Mineral Research 19 (2004) 1241-1249
76. Silverman S.L., Watts N.B., Delmas P.D., et al. Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. Osteoporosis International 18 1 (2007) 25-34
77. McClung M.R., Geusens P., Miller P.D., et al. The effect of risedronate on the risk of hip fracture in elderly women. Hip intervention program study group. The New England Journal of Medicine 344 (2001) 333-340
78. Delmas P.D., Benhamou C.L., Man C., et al. Monthly dosing of 75 mg risedronate on 2 consecutive days a month: efficacy and safety results. Osteoporosis International 19 7 (2008) 1039-1045
79. Siris E., Harris S.T., Rosen C.J., et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clinic Proceedings. Mayo Clinic 81 8 (2006 Aug) 1013-1022
80. Miller P.D., McClung M.R., Macovei L., et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: one year results from the MOBILE study. Journal of Bone and Mineral Research 20 (2005) 1315-1322
81. Delmas P.D., Adami S., Strugala C., et al. Intravenous ibandronate injections in postmenopausal osteoporosis: 1-year results from the dosing intravenous administration (DIVA) study. Arthritis and Rheumatism 54 6 (2006) 1838-1846
82. Adami S., Felsenberg D., Christiansen C., et al. Efficacy and safety of ibandronate given by intravenous injection once every 3 months. Bone 34 (2004) 881-889
83. Miller P.D. Non-vertebral fracture risk reduction with oral bisphosphonates: challenges with interpreting clinical trial data. Current Medical Research and Opinion 24 1 (2008) 107-119
84. Boonen S., Laan R.F., Barton I.P., et al. Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies. Osteoporosis International 16 10 (2005) 1291-1298
85. Cranney A, Wells GA, Yetisir E, et al. Ibandronate for the prevention of nonvertebral fractures: a pooted analysis of individual patient data. Osteoporosis Int 2008; (in press).
86. Harris S.T., Blumenthals W.A., and Miller P.D. Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies. Current Medical Research and Opinion 24 1 (2008) 237-245
87. Miller P.D., Epstein S., Sedarati F., et al. Once-monthly oral ibandronate compared with weekly oral alendronate in postmenopausal osteoporosis: results from the head-to-head MOTION study. Current Medical Research and Opinion 24 1 (2008) 207-213
88. Reid I.R., Brown J.P., Burckhardt P., et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. The New England Journal of Medicine 346 9 (2002 28) 653-661
89. Bolland M.J., Grey A.B., Horne A.M., et al. The effects of intravenous zoledronate on bone turnover and bone density persist for at least 24 months. Journal of Bone and Mineral Research (2008)
90. Lyles K.W., Colon-Emeric C.S., Magaziner J.S., et al. Zoledronic acid in reducing clinical fracture and mortality after hip fracture. The New England Journal of Medicine 357 (2007) 1799-1809
91. McClung M.R., Lewiecki E.M., Cohen S.B., et al. Denosumab in postmenopausal women with low bone mineral density. The New England Journal of Medicine 354 8 (2006) 821-831
92. Lewiecki E.M., Miller P.D., McClung M.R., et al. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. Journal of Bone and Mineral Research 22 12 (2007) 1832-1841
93. Miller P.D., Bolognese M.A., Lewiecki E.M., et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 43 2 (2008) 222-229
94. Frost H. Bone's mechanostat: a 2003 update. The Anatomical Record. Part A, Discoveries in Molecular, Cellular, and Evolutionary Biology 275 2 (2003) 1081-1101
95. Genant HK, Engelke K, Brown JP, et al. Denosumab improves forearm densitometric, geometric and strength indices as measured by QCT in postmenopausal women with low BMD. European Calcified Tissue (in press).
96. Yates J., Barrett-Conner E., Barlas S., et al. Rapid loss of hip fracture protection after estrogen cessation: evidence from the National Osteoporosis Risk Assessment. Obstetrics and Gynecology 103 3 (2004) 440-446
97. Neviaser A.S., Lane J.M., Lenart B.A., et al. Low-energy femoral shaft fractures associated with alendronate use. Journal of Orthopaedic Trauma 22 5 (2008) 346-350
98. Chapurlat R.D., Arlot M., Burt-Pichat B., et al. Microcrack frequency and bone remodeling in postmenopausal osteoporotic women on long-term bisphosphonates: a bone biopsy study. Journal of Bone and Mineral Research 22 10 (2007) 1502-1509
99. Chavassieux P., Seeman E., and Delmas P.D. Insights into material and structural basis of bone fragility from diseases associated with fractures: how determinants of the biomechanical properties of bone are compromised by disease. Endocrine Reviews 28 2 (2007) 151-164
100. Ruggiero S.I., Mehrotra B., Rosenberg T.J., et al. Osteonecrosis of the jaws associated with use of bisphosphonates: a review of 63 cases. Journal of Oral and Maxillofacial Surgery 62 (2004) 527-534
101. Khosla S., Burr D., Cauley J., et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone And Mineral Research. Journal of Bone and Mineral Research 22 10 (2007) 1479-1491
102. Rizzoli R., Burlet N., Cahall D., et al. Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone 42 5 (2008) 841-847
103. Sorenson H.T., Christensen S., Mehnert F., et al. Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study. BMJ (Clinical Research Ed.) 336 7648 (2008 12) 813-816
104. Heckbert S.R., Li G., Cummings S.R., et al. Use of alendronate and risk of incident atrial fibrillation in women. Archives of Internal Medicine 168 8 (2008) 826-831
105. Miller P.D. Treatment of osteoporosis in chronic kidney disease and end-stage renal disease. Current Osteoporosis Reports 3 (2005) 5-12
106. Miller P.D., Roux C., Boonen S., et al. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault Method: a pooled analysis of nine clinical trials. Journal of Bone and Mineral Research 20 (2005) 2105-2115
107. Jamal S.A., Bauer D.C., Ensrud K.E., et al. Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial. Journal of Bone and Mineral Research 22 (2007) 503-508
108. Miller P.D. Is there a role for bisphosphonates in patients with stage 5 chronic kidney disease?. Seminars in Dialysis 20 (2007) 191-197
109. Miller PD. The role of bone biopsy in chronic renal failure. Clinical Journal of the American Society of Nephrology (in press).
110. Boonen S, Sellmeyer DE, Lippuner K, et al. Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women. Kidney International (in press).
111. Lewiecki E.M., and Miller P.D. Renal safety of intravenous bisphosphonates in the treatment of osteoporosis. Expert Opinion on Drug Safety 6 6 (2007) 663-672
112. Black D.M., Boonen S., Delmas P., et al. Review of comparative effectiveness of treatments to prevent fractures. Annals of Internal Medicine 148 11 (2008) 197-213
113. Hosking D.J., Geusens P., and Rizzoli R. Osteoporosis therapy: an example of putting evidence-based medicine into clinical practice. QJM: Monthly Journal of the Association of Physicians 98 6 (2005) 403-413
114. Delmas P.D., Rizzoli R., Cooper C., et al. Treatment of patients with postmenopausal osteoporosis is worthwhile. The position of the international osteoporosis foundation. Osteoporosis International 16 1 (2005) 1-5